PhRMA

OCTOBER 7, 2022

PhRMA submitted comments this week in response to the Department of Health & Human Services (HHS) proposed rule on the Nondiscrimination in Health Programs and Activities. As outlined in our comments, PhRMA supports many policies in the proposed rule that aim to combat discrimination in health programs and activities, including broad application of nondiscrimination provisions, promoting health equity and preventing discriminatory benefit designs.

Insurance 186

Insurance 186

Drug Topics

OCTOBER 7, 2022

SingleCare's 4th annual celebration of the best in pharmacy, from pharmacists to pharmacy technicians and teams across the United States has been announced.

187

187

Pharmacy Times

OCTOBER 7, 2022

There is not yet an FDA-approved treatment available for monkeypox, but existing antiviral agents have been found to be effective in vitro and in animal studies.

FDA 156

FDA 156

Drug Topics

OCTOBER 7, 2022

Early interventions might preserve lung function, particularly in younger patients with frequent asthma exacerbations, say authors.

198

198

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

OCTOBER 7, 2022

New research suggests that MDMA may offer promising benefits to patients with certain unmet psychological treatment needs.

165

165

Pharmaceutical Technology

OCTOBER 7, 2022

Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The agreement aids Provention in leveraging the capabilities and commercial resources of Sanofi to back teplizumab’s launch. The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.

FDA 119

FDA 119

pharmaphorum

OCTOBER 7, 2022

A UK study has found that Merck & Co’s oral COVID-19 therapy Lagevrio was unable to reduce hospitalisations compared to placebo in patients at higher risk from the virus, adding fuel to assertions in some quarters that its authorisation was premature. The 25,000-subject PANORAMIC trial conducted by researchers at Oxford University looked at the addition of a five-day course of Lagevrio (molnupiravir) to standard care in people aged over 50, or adults aged 18 and over with conditions th

Vaccines 118

Vaccines Labelling Hospitals 118

Pharmacy Times

OCTOBER 7, 2022

QR codes are currently used in various health care settings, such as in hospitals for patient verification, but more recently for health care-related education.

Hospitals 123

Hospitals 123

STAT

OCTOBER 7, 2022

A Merck pill used to combat Covid-19 failed to demonstrate it can lower the risk of hospitalization compared with a placebo among adults at a higher risk from the disease, according to the results of a large study conducted in the U.K. The preliminary results of the randomized trial, which involved more than 25,000 participants, showed that taking molnupiravir did speed time to recovery by about six days, which means that patients did get some relief.

Hospitals 109

Hospitals 109

Pharmacy Times

OCTOBER 7, 2022

For patients facing end-of-life care, psychedelic medicines may offer a chance to feel connected with themselves and others during such a difficult time.

123

123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

OCTOBER 7, 2022

Two additional novel AI-generated targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) have been discovered using the Benevolent Platform and selected for AstraZeneca’s (AZ) drug discovery portfolio. These latest discoveries bring the total number of targets selected to date for AZ’s portfolio-entry under the collaboration up to five, with potential for future development milestones and sales-based royalty revenues for London-based BenevolentAI, also.

100

100

Pharmacy Times

OCTOBER 7, 2022

Michael Barr, MD, MBA, MACP, FRCP, discusses the importance of physicians and pharmacists sharing skills to increase positive patient outcomes.

123

123

STAT

OCTOBER 7, 2022

Federal officials significantly reduced the quality scores of next year’s Medicare Advantage plans, a move that was widely expected but will still affect millions of older adults and people with disabilities who have migrated to the growing program. The lower scores also will drain billions of dollars in bonuses that flow to health insurers that get high marks.

Insurance 98

Insurance 98

Pharmacy Times

OCTOBER 7, 2022

Rucaparib is the only PARP inhibitor demonstrated to have better outcomes than a docetaxel-containing control arm, according to researchers.

123

123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

OCTOBER 7, 2022

WASHINGTON — The federal government, which has long struggled to increase Covid-19 vaccinations in rural areas, is starting to take its shots to where the people are: NASCAR races. A vaccination tent at the NASCAR Cup Series in Arizona next month — attended by roughly 100,000 people — is the latest effort devised by Health and Human Services officials and advisers keen to reinvigorate booster rates that have stalled amid public fatigue and skepticism.

Vaccines 98

Vaccines 98

Pharmacy Times

OCTOBER 7, 2022

Farah Towfic, PharmD, MBA, RPh, director, CEO Operations, US Pharmacopeia, details some of the moments that led her to the pharmacy field and the important role that mentorship played in that process.

107

107

STAT

OCTOBER 7, 2022

In the post-Roe landscape, advocates for abortion rights are pinning hopes on telehealth as one way to provide access in states with newly imposed limits. Startups like Abortion on Demand and Hey Jane  have expanded their capacity to offer telemedicine services, prescribing abortion pills by mail in early pregnancy. Pro-access states, including Massachusetts last month, have enacted measures to protect providers of abortion care from legal penalties.

98

98

pharmaphorum

OCTOBER 7, 2022

As we enter October and the Frontiers Health 2022 conference in Milan, we’re shining a spotlight on some of the Steering Committee members who have helped make the event what it is. Here we talk to Fredrik Debong, who cofounded MySugr in 2012 and sold it to Roche Diabetes Care five years later in an eight- to nine-figure deal. A cooling off in digital health investment.

Documentation 98

Documentation Insurance 98

STAT

OCTOBER 7, 2022

In mid-April 2020, as Covid-19 shutdowns and lockdowns were being put in place across the U.S., my grandmother’s health started to decline. With so many unknowns , the assisted living facility where she lived, like most others, had a strict no-visitors policy. When it became clear that my grandmother was in her last hours of life, the facility figured out how to safely allow my aunt into the building for my grandmother’s last breaths.

Assisted Living 98

Assisted Living 98

Pharmaceutical Commerce

OCTOBER 7, 2022

While all drug development efforts are fraught with peril, a growing number of biopharma companies—large and small—are staking a claim in the rare disease treatment space, chasing odds that could yield clinical and financial rewards.

97

97

STAT

OCTOBER 7, 2022

The FDA has announced the set of rules it proposes to enforce for manufacturers to claim that a food product is “healthy.” The proposed rules are a lot better than the labeling anarchy that currently exists. But here’s my bottom line: health claims are not about health. They are about selling food products. The FDA says that a “healthy” product must meet two requirements: It must contain a meaningful amount of food, and it must not contain more than certain upp

Labelling 98

Labelling Packaging FDA 98

European Pharmaceutical Review

OCTOBER 7, 2022

The National Institute of Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s Zeposia ® (ozanimod) for use in England and Wales to treat moderate to severe ulcerative colitis (UC) cases in adults who are intolerant of, or unresponsive to biologics or conventional therapies. UC is an Inflammatory Bowel Disease (IBD) that makes immune system attack the gastrointestinal (GI) tract.

Immunization 94

Immunization 94

STAT

OCTOBER 7, 2022

A senior researcher who was most recently at Johnson & Johnson has emerged as a top candidate to be Biogen’s CEO, according to people familiar with the discussions. The selection of the researcher, Mathai Mammen, until recently the head of R&D at pharmaceutical giant Johnson & Johnson, would be a major departure for Biogen, which has tended to hire corporate operators rather than credentialed scientists to serve as CEO.

98

98

The Thyroid Pharmacist

OCTOBER 7, 2022

When I began my health journey with nutrition, I was skeptical. Could giving up gluten, dairy, and sugar really make a difference? If these foods were that problematic, I would have certainly learned about them in pharmacy school, right? Well, much to my surprise, within three days of giving up these three foods, my bloating, acid reflux, and irritable bowel syndrome vanished!

Immunization 92

Immunization Labelling Compounding FDA 92

STAT

OCTOBER 7, 2022

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

97

97

pharmaphorum

OCTOBER 7, 2022

It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. Is this true? IQVIA has the long term market data, from World Reviews back to 1978, to investigate, and analysed nearly 30 years of launches into leading therapy classes, from multiple eras in the development of the pharmaceutical industry.

FDA 88

FDA 88

STAT

OCTOBER 7, 2022

Health plans trying to reach low-income and underserved customers say they’re being stymied by a decades-old federal rule limiting texting — and they’re framing it as a health equity issue in their bid to change it.  Low-income and underserved patients, they say, are more likely to see and respond to texts about their health than they are to answer calls from unknown numbers or to receive mailed notices, especially if they’re at work or move frequently.

Insurance 97

Insurance 97

European Pharmaceutical Review

OCTOBER 7, 2022

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 percent. Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.

Dosage 87

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 87

STAT

OCTOBER 7, 2022

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda calls for manicuring the Pharmalot campus, hanging with our shortest short person, indulging in still more ancient rituals and, otherwise, simply lounging about. And what about you?

Insurance 94

Insurance Insurance Coverage Pharmaceutical Companies Pharmaceutical Companies 94

pharmaphorum

OCTOBER 7, 2022

TauRx Pharma’s effort to bring a tau-targeting drug for Alzheimer’s disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be getting closer to the finishing line. The phase 3 LUCIDITY trial of tau aggregation inhibitor hydromethylthionine mesylate (HMTM, formerly known as LMTM or LMTX) showed improvements in cognition in patients compared to their performance and baseline, and also seemed to reduce brain atrophy t

FDA 85

FDA Immunization 85

Drug Topics

OCTOBER 7, 2022

Pre-pandemic survey examines effects of heart disease, asthma, and more.

98

98

Pharmacy Times

OCTOBER 7, 2022

New research suggests that acetazolamide and standard loop-diuretic therapy may decrease congestion and prevent future hospitalizations in patients with acute decompensated heart failure.

Hospitals 65

Hospitals 65

Drug Topics

OCTOBER 7, 2022

Your weekly roundup of the latest news from Drug Topics®.

98

98

PharmaVoice

OCTOBER 7, 2022

Pharma execs share their tips for being a better leader.

105

105